[1] Hasse C. Cancerous tumors in the respiratory organs. In: Swaine W. editor. An Anatomical Descriptrion of the Diseases of the Organs of the Circulation and Respiration. England, London: Sydeham Society, 1846:370-5.
[2] Debakey M. Carcinoma of the lung and tobacco smoking: a historical perspective. Ochsner J 1999;1:106-8
[3] Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer, 2013.
[4] Ferlay J, Shin HR, Bray F, et al. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet] Lyon, France: International Agency for Research on Cancer; 2010; 2008 [updated 2010]. Available online: http://globocan.iarc.fr
[5] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30
[6] Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med 2011;32:605-44.
[7] SEER Cancer Statistic Review, 1975-2014 [Internet]. National Cancer Institute 2017 [cited January 13, 2018]. Available online: https://seer.cancer.gov/csr/1975_2014/
[8] Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon (France): International Agency for Research on Cancer; 2013. Available at: http://globocan.iarc.fr
[9] Fishman JA, Allison H, Knowles SB, et al. State laws on tobacco control–United States, 1998. MMWR CDC Surveill Summ 1999;48(3):21–40.
[10] Jemal A, Bray F, Center MM, et al. Global cancer statistic. CA Cancer J Clin 2011; 61(2):69–90.
[11] Stellman SD, Muscat JE, Thompson S, et al. Risk of squamous cell carcinoma and adenocarcinoma of the lung in relation to lifetime filter cigarette smoking. Cancer 1997;80(3):382–8.
[12] Beasley MB, Brambilla E, Travis WD. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 2005;40(2):90–7.
[13] He J, Chen WQ. Chinese cancer registry annual report 2012. Beijing (China): Military Medical Scienc
[14] Howlader N, Noone AM, Krapcho M, et al, editors. SEER Cancer statistics review, 1975-2012. Bethesda (MD): National Cancer Institute; 2015. Available at: http://seer.cancer.gov/csr/1975_2012/.
[15] Torok S, Hegedus B, Laszlo V, et al. Lung cancer in never smokers. Future Oncol 2011;7:1195–211.
[16] Lee YJ, Kim JH, Kim SK, et al. Lung cancer in never smokers: change of a mindset in the molecular era. Lung Cancer 2011;72:9–15.
[17] Wakelee HA, Chang ET, Gomez SL, et al. Lung cancer incidence in never smokers. J Clin Oncol 2007;25:472–8.
[18] Lee YJ, Kim JH, Kim SK, et al. Lung cancer in never smokers: change of a mindset in the molecular era. Lung Cancer 2011;72:9–15.
[19] Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality Worldwide: IARC Cancer Base No. 11 [Internet]. Lyon (France): International Agency for Research on Cancer; 2013. Available at: http://globocan.iarc.fr.
[20] Howlader N, Noone AM, Krapcho M, et al, editors. SEER Cancer statistics review, 1975-2012. Bethesda (MD): National Cancer Institute; 2015. Available at: http:// seer.cancer.gov/csr/1975_2012/.
[21] Jemal A, Bray F, Center MM, et al. Global cancer statistic. CA Cancer J Clin 2011; 61(2):69–90.
[22] Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidence -based clinical practice guidelines (2nd edition). Chest 2007;132(3 Suppl): 29S–55S.
[23] The health consequences of involuntary smoking: a report of the Surgeon General. Washington, DC: US Government Printing Office, US Department of Health and Human Services; 1986. p. 87–8398.
[24] Respiratory health effects of passive smoking: lung cancer and other disorders. Washington, DC: US Government Printing Office, US Environmental Protection Agency; 1992. publication EPA/600/600F.
[25] Peto R. Influence of dose and duration of smoking on lung cancer rates. In: Zaridze D, Peto R, editors. Tobacco: a major international health hazard; proceedings of an international meeting, June 4–6, 1985, Moscow, vol. 74. Lyon (France): World Health Organization, International Agency for Research on Cancer, IARC Science Publication; 1986. p. 23–33.
[26] Centers for Disease Control (CDC). Smoking and health: a national status report. MMWR Morb Mortal Wkly Rep 1986;35(46):709–11.
[27] Stellman SD, Muscat JE, Thompson S, et al. Risk of squamous cell carcinoma and adenocarcinoma of the lung in relation to lifetime filter cigarette smoking. Cancer 1997;80(3):382–8
[28] Raaschou - Nielsen O, Bak H, Sorensen M, et al. Air pollution from traffic and risk for lung cancer in three Danish cohorts. Cancer Epidemiol Biomarkers Prev 2010; 19(5):1284.
[29] Dockery DW, Pope CA III, Xu X, et al. An association between air pollution and mortality in six U.S. Cities. N Engl J Med 1993;329(24):1753–9
[30] Yorifuji T, Kashima S, Tsuda T, et al. Long-term exposure to trafficrelated air pollution and mortality in Shizuoka, Japan. Occup Environ Med 2010;67(2):111–7.
[31] Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidence -based clinical practice guidelines (2nd edition). Chest 2007;132(3 Suppl): 29S–55S
[32] Pawel DJ, Puskin JS. The U.S. Environmental Protection Agency’s assessment of risks from indoor radon. Health Phys 2004;87(1):68–74.
[33] Darby S, Hill D, Deo H, et al. Residential radon and lung cancer–detailed results of a collaborative analysis of individual data on 7148 persons with lung cancer and 14,208 persons without lung cancer from 13 epidemiologic studies in Europe. Scand J Work Environ Health 2006;32(Suppl 1):1–83.
[34] Krewski D, Lubin JH, Zielinski JM, et al. A combined analysis of North American case-control studies of residential radon and lung cancer. J Toxicol Environ Health A 2006;69(7):533–97.
[35] Lubin JH, Zuo Yuan W, Boice JD, et al. Risk of lung cancer and residential radon in China: pooled results of two studies. Int J Cancer 2004;109(1):132–7.
[36] Hendee WR. Estimation of radiation risks: BEIR V and its significance for medicine. JAMA 1992;268(5):620–4.
[37] Peto R, Doll R, Buckley JD, et al. Can dietary beta-carotene materially reduce human cancer rates? Nature 1981;290(5803):201–8.
[38] Alberg AJ, Samet JM. Epidemiology of lung cancer. In: Sadler MJ, Caballero B, Strain JJ, editors. Encyclopedia of human nutrition. London: Academic Press; 2005. p. 272–84
[39] Kuman, V.; Abbas, A.; Fausto, N.; Robbins, S.; Cotran, R. Robbins and Cotran Pathologic Basis of Disease; Elsevier Saunders: Philadelphia, PA, USA, 2005; p. 759.
[40] Travis, W.D. Update on Small Cell Carcinoma and Its Differentiation from Squamous Cell Carcinoma and Other Non-Small Cell Carcinomas. Mod. Pathol. 2012, 25, S18–S30. [CrossRef]
[41] Chan, B.A.; Coward, J.I.G. Chemotherapy Advances in Small-Cell Lung Cancer. J. Thorac. Dis. 2013, 5 (Suppl. S5), S565–S578. [CrossRef]
[42] Edge, S.B.; Compton, C.C. The American Joint Committee on Cancer: The 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Ann. Surg. Oncol. 2010, 17, 1471–1474. [CrossRef]
[43] Usman Ali, M.; Miller, J.; Peirson, L.; Fitzpatrick-Lewis, D.; Kenny, M.; Sherifali, D.; Raina, P. Screening for Lung Cancer: A Systematic Review and Meta-Analysis. Prev. Med. 2016, 89, 301–314. [CrossRef] [PubMed]
[44] Nanavaty, P.; Alvarez, M.S.; Alberts, W.M. Lung Cancer Screening: Advantages, Controversies, and Applications. Cancer Control 2014, 21, 9–14. [CrossRef] [PubMed]
[45] Updated USPSTF Lung Cancer Screening Guidelines Would Help Save Lives. Available online: https://www.acr.org/MediaCenter/ACR-News-Releases/2020/Updated-USPSTF-Lung-Cancer-Screening-Guidelines-Would-Help-Save-Lives (accessed on 22 April 2021)
[46] Sobue, T.; Moriyama, N.; Kaneko, M.; Kusumoto, M.; Kobayashi, T.; Tsuchiya, R.; Kakinuma, R.; Ohmatsu, H.; Nagai, K.; Nishiyama, H.; et al. Screening for Lung Cancer with Low-Dose Helical Computed Tomography: Anti-Lung Cancer Association Project. JCO 2002, 20, 911–920. [CrossRef] [PubMed]
[47] Toyoda, Y.; Nakayama, T.; Kusunoki, Y.; Iso, H.; Suzuki, T. Sensitivity and Specificity of Lung Cancer Screening Using Chest Low-Dose Computed Tomography. Br. J. Cancer 2008, 98, 1602–1607. [CrossRef] [PubMed]
[48] Kurie, J.M.; Lee, J.S.; Morice, R.C.; Walsh, G.L.; Khuri, F.R.; Broxson, A.; Ro, J.Y.; Franklin, W.A.; Yu, R.; Hong, W.K. Autofluorescence Bronchoscopy in the Detection of Squamous Metaplasia and Dysplasia in Current and Former Smokers. J. Natl. Cancer Inst. 1998, 90, 991–995. [CrossRef]
[49] Kennedy, T.C.; Hirsch, F.R.; Miller, Y.E.; Prindiville, S.; Murphy, J.R.; Dempsey, E.; Proudfoot, S.; Bunn, P.A.; Franklin, W.A. A Randomized Study of Fluorescence Bronchoscopy versus White-Light Bronchoscopy for Early Detection of Lung Cancer in High Risk Patients. Lung Cancer 2000, 1 (Suppl. S1), 244–245. [CrossRef]
[50] Pennell, N.A.; Arcila, M.E.; Gandara, D.R.; West, H. Biomarker Testing for Patients with Advanced Non–Small Cell Lung Cancer: Real-World Issues and Tough Choices. Am. Soc. Clin. Oncol. Educ. Book 2019, 39, 531–542. [CrossRef] [PubMed]
[51] Gazdar, A.F.; Minna, J.D. Angiogenesis and the Multistage Development of Lung Cancers. Clin. Cancer Res. 2000, 6, 1611–1612.
[52] Howington JA, Blum MG, Chang AC, et al. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143:e278S-313S
[53] Chemotherapy in non-small cell lung cancer: a metaanalysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
[54] Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 2008;13 Suppl 1:5-13.
[55] Masters GA, Temin S, Azzoli CG, et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015;33:3488-515.
[56] Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-8.
[57] Tekea, M. E. (2021). Review on Consumer Preference of Milk and Milk Product in Ethiopia. In International Journal of Horticulture, Agriculture and Food science (Vol. 5, Issue 2, pp. 1–8). https://doi.org/10.22161/ijhaf.5.2.1
[58] Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-91.
[59] Baxter, G. (2023). Towards Carbon Neutral Airport Operations Through the Use of Renewable Energy Sources: The Case of Chhatrapati Shivaji Maharaj and Indira Gandhi International Airports, India. In International Journal of Environment, Agriculture and Biotechnology (Vol. 8, Issue 2, pp. 084–100). https://doi.org/10.22161/ijeab.82.9
[60] Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-smallcell lung cancer. N Engl J Med 2002;346:92-8.
[61] Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21:3016-24
[62] Amini A, Yeh N, Gaspar LE, et al. Stereotactic body radiation therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: a review. Radiat Oncol 2014;9:210.
[63] Grutters JP, Kessels AG, Pijls-Johannesma M, et al. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiother Oncol 2010;95:32-40.
[64] Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 2009;75:677-82.
[65] BioRender (2019). Early Screening of Lung Cancer. https://app.biorender.com/biorender-templates/figures/all/t-5e2074be9031520086585b8b-early-screening-of-lung-cancer
[66] Wang H, Rayburn ER, Wang W, Kandimalla ER, Agrawal S et al. Chemotherapy and chemosensitization of nonsmall cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9. Mol.Cancer Ther. 2006; 5: 1585–92.
[67] Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill Jet al. Autologous dendritic cell vaccines for non-smallcell lung cancer. J. Clin. Oncol. 2004; 22: 2808–15.
